Journal articleMelanoma Res2018
CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
- Journal
- Melanoma Res
- Published
- 1 June 2018
- Citations
- 6
- Type
- Article
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
CDKN2A germline mutations increase the risk of melanoma development and are present in 20 and 10% of familial and multiple melanoma cases, respectively. Pancreatic cancer has been associated with CDKN2A in some populations and, accordingly, its presence in first-degree or second-degree relatives of a melanoma patient is considered as a criterion for genetic testing. … Excerpt only: this text is the publisher’s. Read it in full at the source.